查詢結果分析
來源資料
相關文獻
- Low dose Intravenous Cyclophosphamide-Induced Ovarian Failure in Chinese Patients with Lupus Nephritis
- 艾灸對小鼠巨噬細胞吞噬功能的影響
- Clinicopathologic Findings and Outcome in Lupus Nephritis Patients with Renal Biopsy
- In Vivo Stimulation of Myelopoiesis in Cyclophosphamide-Treated Mice by Purified Human GM-CSF
- 晚發型系統性紅斑性狼瘡合併抗利尿激素分泌不當症候群--病例報告及文獻回顧
- 兒童狼瘡性腎炎
- 脈衝Cyclophosphamide在狼瘡性腎炎治療之角色
- 四物湯造血機能之探討
- Intravenous Cyclophosphamide Pulse Therapy on Children with Severe Active Lupus Nephritis
- Intermittent Intravenous Treatment of Lupus Nephritis with Cyclophosphamide: A Four-year Experience with Twenty-four Patients
頁籤選單縮合
題 名 | Low dose Intravenous Cyclophosphamide-Induced Ovarian Failure in Chinese Patients with Lupus Nephritis=在有狼瘡性腎炎的華人因低劑量環磷醯胺治療引起的卵巢功能衰竭 |
---|---|
作 者 | 林靖才; 陳怡行; 陳得源; 黃文男; 藍忠亮; | 書刊名 | 中華民國風濕病雜誌 |
卷 期 | 21:2 2007.12[民96.12] |
頁 次 | 頁53-58 |
分類號 | 415.695 |
關鍵詞 | 狼瘡性腎炎; 環磷醯胺; 卵巢功能衰竭; 華人狼瘡病患; Lupus nephritis; Cyclophosphamide; Ovarian failure; Chinese lupus patients; |
語 文 | 英文(English) |
中文摘要 | 前言:環磷醯胺在治療狼瘡性腎炎的效果已經是證據充分的。然而只有少數研究探討其在狼瘡性腎炎的華人病患對卵巢功能的影響。 方法:106 名狼瘡性腎炎的病患接受環磷醯胺治療,我們研究病患接受環磷醯胺治療的起始年紀、環磷醯胺服用的總劑量及使用途徑對於卵巢功能衰竭的影響。 結果:在所有病患,環磷醯胺的平均累積劑量少於4.5 克。藉由統計回歸法我們發現卵巢功能衰竭與環磷醯胺治療的起始年紀有統計學上的意義。沒有任何小於 25 歲的病患在開始靜脈注射環磷醯胺治療後有卵巢功能衰竭的情形;介於26-44 歲之間的患者有15.7% 會發展成永久性的卵巢功能衰竭,且在所有年齡大於45 歲的患者接受靜脈注射環磷醯胺治療後會導致卵巢功能衰竭(p<0.0001) 。接受口服環磷醯胺治療之病患比靜脈治療病患易引起卵巢功能衰竭(p=0.024)。 結論:我們的研究顯示年輕的患者對環磷醯胺治療引起的卵巢功能衰竭危險性較小。每月靜脈注射給予亦較每日口服給藥對卵巢影響較小。 |
英文摘要 | Objective: The efficacy of cyclophosphamide (CYC) in the treatment of lupus nephritis has been well documented. However, few studies regarding its effects on ovarian function in Chinese lupus patients have been reported. Method: One hundred and six lupus nephritis patients treated with CYC, the effects of the starting age of CYC treatment, total doses of CYC administration and routes of administration on ovarian failure were investigated. Results: The mean cumulative dose of CYC was less than 4.5 gm in all patients. By logistic regression, we found that ovarian failure was significantly correlated with starting age of intravenous CYC treatment. None of the patients that started intravenous CYC therapy before the age of 25 had ovarian failure while 15.7% of those starting CYC treatment between the ages of 26 to 44 developed permanent amenorrhea and all patients receiving CYC after the age of 45 developed ovarian failure (p<0.0001). Patients taking oral CYC had a higher frequency of developing permanent amenorrhea compared with an intravenous route (p=0.024). Conclusion: We conclude that younger patients had a decreased risk of developing CYC-induced ovarian failure. Monthly intravenous administration has less ovarian toxicity than a daily oral regiment. |
本系統中英文摘要資訊取自各篇刊載內容。